S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Palo Alto Networks aims at cyber security leadership
3 Reasons the Capital One-Discover merger is a big deal
Is Gold Really Boring? (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Teladoc Health gaps down to support level after weak guidance
Housing data weakens, but Toll Brothers stock is still a buy
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Palo Alto Networks aims at cyber security leadership
3 Reasons the Capital One-Discover merger is a big deal
Is Gold Really Boring? (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Teladoc Health gaps down to support level after weak guidance
Housing data weakens, but Toll Brothers stock is still a buy
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Palo Alto Networks aims at cyber security leadership
3 Reasons the Capital One-Discover merger is a big deal
Is Gold Really Boring? (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Teladoc Health gaps down to support level after weak guidance
Housing data weakens, but Toll Brothers stock is still a buy
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Palo Alto Networks aims at cyber security leadership
3 Reasons the Capital One-Discover merger is a big deal
Is Gold Really Boring? (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Teladoc Health gaps down to support level after weak guidance
Housing data weakens, but Toll Brothers stock is still a buy

Atara Biotherapeutics (ATRA) Earnings Date, Estimates & Call Transcripts

$0.80
-0.04 (-4.78%)
(As of 02/21/2024 ET)

Earnings Summary

Upcoming
Earnings Date
May. 6Estimated
Actual EPS
(Feb. 22)
-$0.48 Missed By -$0.48
Skip Charts & View Estimated and Actual Earnings Data

ATRA Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

ATRA Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Atara Biotherapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20241($0.62)($0.62)($0.62)
Q2 20241($0.62)($0.62)($0.62)
Q3 20241($0.63)($0.63)($0.63)
Q4 20241($0.64)($0.64)($0.64)
FY 20244($2.51)($2.51)($2.51)

ATRA Earnings Date and Information

Atara Biotherapeutics last released its quarterly earnings results on February 22nd, 2024. The biotechnology company reported ($0.48) earnings per share (EPS) for the quarter. Atara Biotherapeutics has generated ($2.78) earnings per share over the last year (($2.78) diluted earnings per share). Earnings for Atara Biotherapeutics are expected to grow in the coming year, from ($2.62) to ($1.78) per share. Atara Biotherapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, May 6th, 2024 based off prior year's report dates.

Atara Biotherapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/6/2024
Estimated)
------- 
2/22/2024--($0.48)($0.48)---
11/1/2023Q3 2023($0.63)($0.66)($0.03)($0.66)$2.20 million$2.14 million    
8/8/2023Q2 2023($0.65)($0.68)($0.03)($0.68)$3.36 million$0.96 million
5/8/2023Q1 2023($0.40)($0.72)($0.32)($0.72)$37.67 million$1.23 million
2/8/2023Q4 2022($0.61)($0.72)($0.11)($0.72)$60.00 million$0.22 million
11/8/2022Q3 2022($0.78)($0.82)($0.04)($0.82)$4.37 million$4.46 million
8/8/2022Q2 2022($0.91)($0.31)+$0.60($0.80)$8.84 million$51.58 million    
5/5/2022Q1 2022($0.98)($0.87)+$0.11($0.87)$6.58 million$7.31 million    
2/28/2022Q4 2021($0.60)($0.96)($0.36)($0.96)$47.75 million$7.55 million    
11/4/2021Q3 2021($0.92)($0.90)+$0.02($0.90)$5.31 million$5.37 million    
8/8/2021Q2 2021($0.88)($0.91)($0.03)($0.91)$6.32 million$3.87 million    
5/3/2021Q1 2021($0.92)($0.86)+$0.06($0.86)$7.19 million$3.55 million  
2/28/2021Q4 2020($0.73)($0.95)($0.22)($0.95)--  












Atara Biotherapeutics Earnings - Frequently Asked Questions

When is Atara Biotherapeutics's earnings date?

Atara Biotherapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, May 6th, 2024 based off last year's report dates. Learn more on ATRA's earnings history.

How much revenue does Atara Biotherapeutics generate each year?

Atara Biotherapeutics (NASDAQ:ATRA) has a recorded annual revenue of $63.57 million.

How much profit does Atara Biotherapeutics generate each year?

Atara Biotherapeutics (NASDAQ:ATRA) has a recorded net income of -$228.30 million. ATRA has generated -$2.78 earnings per share over the last four quarters.

What is Atara Biotherapeutics's EPS forecast for next year?

Atara Biotherapeutics's earnings are expected to grow from ($2.62) per share to ($1.78) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:ATRA) was last updated on 2/22/2024 by MarketBeat.com Staff